Shares of Simulations Plus, Inc. (NASDAQ:SLP) have been assigned a consensus broker rating score of 2.00 (Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy rating.
Brokerages have set a 1-year consensus price objective of $37.00 for the company and are expecting that the company will post $0.09 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Simulations Plus an industry rank of 64 out of 256 based on the ratings given to related companies.
A number of equities analysts have commented on the company. ValuEngine cut Simulations Plus from a “strong-buy” rating to a “buy” rating in a report on Friday. BidaskClub upgraded shares of Simulations Plus from a “buy” rating to a “strong-buy” rating in a report on Monday, July 15th. Finally, Zacks Investment Research upgraded shares of Simulations Plus from a “hold” rating to a “strong-buy” rating and set a $37.00 target price for the company in a report on Friday, July 19th.
Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Wednesday, July 10th. The technology company reported $0.16 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.02. Simulations Plus had a return on equity of 23.48% and a net margin of 24.09%. The company had revenue of $9.94 million for the quarter, compared to analysts’ expectations of $9.85 million. As a group, equities analysts forecast that Simulations Plus will post 0.46 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Thursday, July 25th were paid a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a yield of 0.63%. The ex-dividend date of this dividend was Wednesday, July 24th. Simulations Plus’s dividend payout ratio (DPR) is presently 48.00%.
In related news, Director Walter S. Woltosz sold 18,500 shares of Simulations Plus stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $25.67, for a total transaction of $474,895.00. Following the sale, the director now owns 5,178,083 shares of the company’s stock, valued at approximately $132,921,390.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 31.57% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SLP. Advisor Group Inc. raised its position in shares of Simulations Plus by 156.9% in the fourth quarter. Advisor Group Inc. now owns 2,112 shares of the technology company’s stock valued at $42,000 after purchasing an additional 1,290 shares during the period. BNP Paribas Arbitrage SA lifted its position in Simulations Plus by 59,875.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,399 shares of the technology company’s stock worth $51,000 after buying an additional 2,395 shares in the last quarter. Metropolitan Life Insurance Co. NY purchased a new stake in Simulations Plus in the 4th quarter worth approximately $79,000. MetLife Investment Advisors LLC bought a new position in shares of Simulations Plus during the 4th quarter valued at $108,000. Finally, Bailard Inc. bought a new position in shares of Simulations Plus during the 2nd quarter valued at $208,000. Institutional investors and hedge funds own 41.26% of the company’s stock.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Featured Story: When can a hold rating present a buying opportunity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.